1.04Open1.04Pre Close0 Volume83 Open Interest190.00Strike Price0.00Turnover63.46%IV22.84%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier26DDays to Expiry1.04Extrinsic Value100Contract SizeAmericanOptions Type-0.0551Delta0.0027Gamma235.47Leverage Ratio-0.0861Theta-0.0094Rho-12.98Eff Leverage0.0730Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet